Today's Rundown Days after its $63M boost, Imara gains former Pfizer rare disease executive as CMO GenFit gets $135M Nasdaq IPO for NASH, PBC hopes ProQR spins out skin disease drug into nonprofit-backed startup Ono pumps cash into U.K. immuno-oncology R&D effort Treating heart failure by targeting fat metabolism Novartis snags blockbuster OK for secondary progressive multiple sclerosis drug Mayzent Featured Story | | | Wednesday, March 27, 2019 Sickle cell disease biotech Imara has nabbed Pfizer’s clinical rare disease lead Willem H. Scheele, M.D., as its new chief medical officer. |
|
|
Top Stories Wednesday, March 27, 2019 Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO. Wednesday, March 27, 2019 ProQR Therapeutics has spun out its early-phase oligonucleotide treatment for a rare inherited skin disorder to form a new company. The spinout, Wings Therapeutics, starts life with a phase 1/2 asset and funding from a disease-focused nonprofit. Wednesday, March 27, 2019 Ono Pharmaceutical has formed an immuno-oncology pact with Cancer Research UK and LifeArc. The deal gives Ono the chance to license antibodies and small molecules advanced by its partners. Wednesday, March 27, 2019 By burning fats and glucose, our hearts get the energy necessary to function well. Scientists at Ohio State University have identified a compound that's key in fat metabolism but that falls when the heart becomes stressed. Restoring it could reduce the risk of heart failure, they found. Wednesday, March 27, 2019 Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis. The next challenge? Getting doctors to diagnose it. | This week's sponsor is Covance. | | | Advancing a Diabetes Multi-Registration Program
Learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Download the Case Study now. |
Resources Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! Calling Europe – Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 